MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,772,564
EPS
-$0.18
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-06-30
2025-03-31
2024-12-31
2024-09-30
Product revenue
0
-
-
-
Product cost of sales
0
-
-
-
Gross income
0
-
-
-
Stock based compensation expenses
104,854
84,636
377,187.5*
13,762
Research and development expenses
873,472
1,545,513
646,282*
707,747
Administrative expenses
894,297
841,685
975,244*
1,104,130
Series g warrant issuance expenses
0
-
242,376.25*
-
Series f-1 warrant issuance expenses
0
-
134,774.25*
-
Gain (losses) on fair value of derivative liability
-
-
-
-356,000
Loss from operations
-1,872,623
-2,471,834
-2,375,864*
-1,825,639
Changeinfairvalueofmarketablesecurities
-
-
-
4,746
Unrealized gain on marketable securities
-
-
167.75*
-
Gainlossonsalesofmarketablesecurities
-
-
-
551
(gain)/loss on sale of marketable securities
0
-
244*
-
Interest and dividend income
57,575
62,512
74,160.5*
163,951
Gain on sale of investments
-
2,176
-
-
Casualtygainloss
-
-
-
100,000
Change in fair value of derivatives liabilities
19,000
1,284,000
-
-
Change in fair value of warrant liabilities
0
-
1,531,983.75*
17,000
Change in fair value of derivatives liabilities
-
-
-97,000*
-
Loss on issuance of series g convertible preferred stock
0
-
1,277,250*
-
Loss on issuance of series f-1 convertible preferred stock
0
-
934,250*
-
Casualty loss/(gain)
-
-
25,000*
-
Unrealized loss on marketable securities
-
-1,597
-
-
Change in fair value of marketable securities
-147
-
-
-
Total other (income)/expense
76,428
1,347,091
-3,740,911.5*
-103,752
Loss before income tax
-1,796,195
-1,124,743
-6,116,775.5*
-1,929,391
Income tax benefit
0
-
0*
-
Net loss
-1,796,195
-1,124,743
-6,116,775.5*
-1,929,391
Preferred stock dividends
976,369
813,496
1,509,297*
751,052
Net loss attributable to common stockholders
-2,772,564
-1,938,239
-7,626,072.5
-2,680,443
Basic EPS
-0.18
-0.36
-2.91
-1.11
Diluted EPS
-0.18
-0.36
-2.91
-1.11
Basic Average Shares
15,698,856
5,349,662
2,620,212
2,415,089
Diluted Average Shares
15,698,856
5,349,662
2,620,212
2,415,089
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$2,772,564
(73.19%↑ Y/Y)
Net loss
-$1,796,195
(81.22%↑ Y/Y)
Preferred stock dividends
$976,369
(25.60%↑ Y/Y)
Interest and dividend
income
$57,575
(172.25%↑ Y/Y)
Change in fair value of
derivatives liabilities
$19,000
Loss before income
tax
-$1,796,195
(81.22%↑ Y/Y)
Total other
(income)/expense
$76,428
(101.23%↑ Y/Y)
Change in fair value of
marketable securities
-$147
Loss from operations
-$1,872,623
(44.43%↑ Y/Y)
Administrative expenses
$894,297
(-12.35%↓ Y/Y)
Research and development
expenses
$873,472
(117.77%↑ Y/Y)
Stock based
compensation expenses
$104,854
(-76.15%↓ Y/Y)
Buy us a coffee
TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (TNFA)